HALO - Bristol Myers succeeds in Phase 3 trial for subcutaneous Opdivo
2023-10-19 07:49:48 ET
More on Bristol-Myers, Halozyme, etc.
- Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud
- Bristol-Myers: Out Of Favor (Rating Upgrade)
- Bristol-Myers Squibb: How Cheap Is Cheap Enough?
- Bristol Myers' Opdivo gets FDA approval for expanded use in skin cancer
- Bristol Myers adds second CAR-T asset in Cellares deal
For further details see:
Bristol Myers succeeds in Phase 3 trial for subcutaneous Opdivo